title: [Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation].
abstract: Propafenone efficacy in conversion of atrial fibrillation to sinus rhythm has been well documented. In this study we considered propafenone efficacy according to a graduated protocol of administration. Forty-two patients with recent-onset atrial fibrillation, without left ventricular failure, ischemic symptoms and in absence of antiarrhythmical treatment, were treated according to the following protocol: propafenone 1 mg/kg i.v. (5 min) followed, in the non-responder patient group, by a second dose, 0.5 mg/kg i.v. (15 min). Patients with persistent atrial fibrillation received 900 mg/daily of propafenone per os, at home for two days. Thereafter, patients still not restored to sinus rhythm were considered non-responders. Patients who were converted to sinus rhythm received 450 mg daily of the drug (oral administration), at home, as antiarrhythmical prophylaxis, for three months. Thirty-nine patients were converted to sinus rhythm (92.8%), 24 of them after intravenous propafenone (57.2%), and the other 15 (35.6%) after oral administration of the drug. The average heart rate in patients not converted to sinus rhythm with intravenous propafenone was significantly reduced after drug administration, compared to basal values (from 136.4 +/- 18.1 to 107.1 +/- 17.6, p < 0.01), allowing home treatment. No major cardiac effects were observed after infusion, nor after oral administration of propafenone. During a three-month follow-up we observed 3 cases of relapsed atrial fibrillation and 2 discontinued treatments due to minor gastroenteric side effects. In conclusion, propafenone therapy in ambulatory regimen is safe and effective in patients with recent-onset atrial fibrillation. In many patients refractory to IV treatment, further therapeutic success may be achieved following oral propafenone administration.
authors.affiliation: Unità Operativa di Cardiologia, Ospedale S. Pietro Igneo, Fucecchio.
authors.forename: M
authors.initials: M
authors.lastname: Margheri
authors.forename: G
authors.initials: G
authors.lastname: Fradella
authors.forename: M
authors.initials: M
authors.lastname: Maioli
authors.forename: M
authors.initials: M
authors.lastname: Paterni
authors.forename: P
authors.initials: P
authors.lastname: Bartoli
authors.forename: F
authors.initials: F
authors.lastname: Bonechi
authors.forename: A
authors.initials: A
authors.lastname: Brandinelli
authors.forename: F
authors.initials: F
authors.lastname: Mazza
authors.forename: M
authors.initials: M
authors.lastname: Sansoni
authors.forename: A
authors.initials: A
authors.lastname: Zipoli
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D002985:Clinical Protocols; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D011405:Propafenone
vernacular_title: Efficacia del propafenone e.v. e per os nel trattamento ambulatoriale della fibrillazione atriale di recente insorgenza.